Cantex Pharmaceuticals, Inc.: Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

(marketscreener.com) Cantex's once daily, orally administered, azeliragon inhibits interactions of the receptor for advanced glycation end products Researchers showed RAGE inhibition to be a potential target for treatment of triple-negative breast cancer suppressing tumor progression and metastasis WESTON, Fla., Aug. 10, 2023 /PRNewswire/ -- Cantex...https://www.marketscreener.com/quote/stock/VTV-THERAPEUTICS-INC-23175037/news/Cantex-Pharmaceuticals-Announces-Article-Published-in-npj-Breast-Cancer-Highlighting-Potential-Role-44578354/?utm_medium=RSS&utm_content=20230810